OSIR : Summary for OSIRIS THERAPE INC COM STK USD0 - Yahoo Finance

U.S. Markets open in 2 hrs 29 mins

Osiris Therapeutics, Inc. (OSIR)


NasdaqGM - NasdaqGM Delayed Price. Currency in USD
Add to watchlist
3.95+0.02 (+0.51%)
At close: 3:59PM EDT
People also watch
CYTXCURPSTIOPXAVNDA
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close3.93
Open3.88
Bid0.00 x
Ask0.00 x
Day's Range3.87 - 4.00
52 Week Range2.67 - 7.39
Volume24,888
Avg. Volume210,859
Market Cap136.09M
Beta1.15
PE Ratio (TTM)94.05
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield0.00 (0.00%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire14 hours ago

    Osiris Therapeutics, Inc. Completes Restatement of 2014 Financial Statements

    COLUMBIA, Md., March 27, 2017-- Osiris Therapeutics, Inc., a leading regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, announced ...

  • Osiris Therapeutics, Inc.: Sudden move in price, will it continue?
    Capital Cube7 days ago

    Osiris Therapeutics, Inc.: Sudden move in price, will it continue?

    Categories: Yahoo Finance Osiris Therapeutics, Inc. relative valuation is UNDERVALUED and it has a fundamental analysis score of 86. Our analysis is based on comparing Osiris Therapeutics, Inc. with the following peers – Vericel Corporation, Integra LifeSciences Holdings Corporation, Geron Corporation, Johnson & Johnson, Xtant Medical Holdings, Inc., CONMED Corporation, Nektar Therapeutics and Pluristem Therapeutics Inc. (VCEL-US, IART-US, ... Read more (Read more...)

  • Accesswire14 days ago

    NASDAQ Decides to Delist Osiris Therapeutics, Pulmatrix Deals with Research Cost Overruns

    NEW YORK, NY / ACCESSWIRE / March 14, 2017 / The competition between Osiris Therapeutics and competitor PTC has ended with an unceremonious thud. Osiris has come to the end of its NASDAQ run today, after ...